Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial-Reference-Cited by-同舟云学术

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

Published:2011-09-29 Issue:3 Volume:39 Page:242-252
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:

Author:

IGARASHI Atsuyuki,KATO Takeshi,KATO Mai,SONG Michael,NAKAGAWA Hidemi,

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1346-8138.2011.01347.x/fullpdf

Reference38 articles.

1. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis;Chandran;J Autoimmun,2010

2. Psoriasis;Schön;N Engl J Med,2005

3. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population;Jee;Br J Dermatol,1998

4. The prevalence of psoriasis in the Mongoloid race;Yip;J Am Acad Dermatol,1984

5. A survey of psoriasis patients in Japan from 1982 to 2001;Kawada;J Dermatol Sci,2003

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short Term Efficacy of Biological Treatment for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis;2024-08-05

2. Ustekinumab: In Psoriasis and Beyond —A Derm atological Perspective;Journal of Pharmacology and Pharmacotherapeutics;2024-05-08

3. Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients;Journal of Dermatological Treatment;2024-03-26

4. Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis;JEADV Clinical Practice;2024-01-05

5. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study;BioDrugs;2023-11-22